Kamolz Thomas, Granderath Frank A, Pointner Rudolph
Division of Clinical Psychology, Public Hospital of Zell am See, Austria.
Surg Laparosc Endosc Percutan Tech. 2003 Jun;13(3):155-60. doi: 10.1097/00129689-200306000-00003.
It is well known that several patient-related factors are able to affect the surgical outcome such as quality of life or symptom relief after laparoscopic antireflux surgery. The aim of the current study was to evaluate and compare surgical outcome up to 1 year after laparoscopic antireflux surgery in relation to patients' subjective degree of compliance with former antireflux medication. Based on a three-level grading of subjective compliance with primary antireflux medication, a total of 140 patients undergoing antireflux surgery were divided into three subgroups: group 1/TC (totally compliant; n = 60), group 2/PC (partially compliant; n = 49); and group 3/NC (noncompliant; n = 31). Gastrointestinal Quality of Life Index (GIQLI), satisfaction with surgery, and the subjective degree of dysphagia as well as traditional outcome data (e.g., DeMeester score, lower esophageal sphincter pressure, side effects) were evaluated in all patients. As a result of surgery, only patients out of group 1/TC (GIQLI, preoperative 86.3 + 9.3 vs. 1 year postoperatively 123.1 + 7.2 points) and group 2/PC (GIQLI, preoperative 94.2 + 8.6 vs. 1 year postoperatively 120.8 + 7.8 points) showed a significant quality of life improvement that remained stable for at least 1 year (P < 0.05-0.01). In contrast, group 3/NC (GIQLI, preoperative 100.2 + 6.1 vs. 1 year postoperatively 117.2 + 9.8 points) patients had no significant quality of life improvement and patient satisfaction with surgery was less good when compared with that of the other groups. In these patients, also the subjective degree of postoperative dysphagia was significantly (P < 0.05-0.001) higher during the 1-year follow-up when compared with patients from group 1/TC or group 2/PC. A total of 42% of group 3/NC patients reported surgical side effects, whereas only 3% from group 1/TC and 10% from group 2/PC stated to be affected by any new symptoms (P < 0.0001). None of group 1/TC or group 2/PC patients suffered from recurrent symptoms or underwent laparoscopic reoperation. Of group 3/NC, a total of four patients (13%) needed any kind of additional intervention in relation to antireflux surgery (reoperation, n = 3; pneumatic dilatation, n = 1). There were no significant differences between the three groups when postoperative values of esophageal manometry and 24-hour pH monitoring were compared. What the current study does show is that the efficacy and the surgical outcome after laparoscopic antireflux surgery partly depends on the subjective degree of patient compliance with primary antireflux medication. Patients with no compliance in relation to former antireflux medication should generally not be refused antireflux surgery. But these patients should be evaluated with great care before surgery and should also be informed that surgical outcome may be affected in several aspects.
众所周知,一些与患者相关的因素能够影响手术结果,比如腹腔镜抗反流手术后的生活质量或症状缓解情况。本研究的目的是评估并比较腹腔镜抗反流手术后长达1年的手术结果与患者对先前抗反流药物的主观依从程度之间的关系。基于对主要抗反流药物主观依从性的三级分级,总共140例接受抗反流手术的患者被分为三个亚组:第1组/完全依从组(TC,完全依从;n = 60),第2组/部分依从组(PC,部分依从;n = 49);以及第3组/不依从组(NC,不依从;n = 31)。对所有患者评估了胃肠道生活质量指数(GIQLI)、对手术的满意度、吞咽困难的主观程度以及传统的手术结果数据(如DeMeester评分、食管下括约肌压力、副作用)。手术结果显示,只有第1组/完全依从组(GIQLI,术前86.3±9.3分,术后1年123.1±7.2分)和第2组/部分依从组(GIQLI,术前94.2±8.6分,术后1年120.8±7.8分)的患者生活质量有显著改善,且至少持续1年保持稳定(P < 0.05 - 0.01)。相比之下,第3组/不依从组(GIQLI,术前100.2±6.1分,术后1年117.2±9.8分)的患者生活质量没有显著改善,并且与其他组相比,患者对手术的满意度较低。在这些患者中,术后1年随访期间吞咽困难的主观程度也显著高于第1组/完全依从组或第2组/部分依从组的患者(P < 0.05 - 0.001)。第3组/不依从组共有42%的患者报告有手术副作用,而第1组/完全依从组只有3%,第2组/部分依从组只有10%表示受到任何新症状的影响(P < 0.0001)。第1组/完全依从组或第2组/部分依从组的患者均未出现复发症状或接受腹腔镜再次手术。第3组/不依从组中,共有4例患者(13%)需要针对抗反流手术进行任何形式的额外干预(再次手术,n = 3;气囊扩张,n = 1)。比较三组术后食管测压和24小时pH监测值时,未发现显著差异。当前研究确实表明,腹腔镜抗反流手术后的疗效和手术结果部分取决于患者对主要抗反流药物的主观依从程度。与先前抗反流药物不依从的患者一般不应被拒绝进行抗反流手术。但这些患者在手术前应进行仔细评估,并且还应告知他们手术结果可能在几个方面受到影响。